January 2002
Royal Society of Medicine: Medicines;2002, p470
Reference Entry
This article presents information on Reductil, a proprietary preparation of the appetite suppressant sibutramine. It can be used to assist in obesity treatment, and is available in capsules.


Related Articles

  • Sibutramine.  // Reactions Weekly;7/23/2005, Issue 1061, p15 

    Presents case study of cardiomyopathy in a 36-year-old man. Development of the disease during treatment with sibutramine for obesity; Dosage of sibutramine given to the patient; Factors that led to the improvement of the patient's condition and echocardiographic measurements.

  • SIBUTRAMINE. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2009, p754 

    The article presents information on sibutramine, an appetite suppressant drug, including dosage, usage, adverse reactions, side effects, precautions, and possible interaction with other drugs.

  • Medication, lifestyle chances affect weight. Arias, Donya C. // Nation's Health;Jan/Feb2006, Vol. 36 Issue 1, p22 

    The article reports on the study of the impact of weight-loss medication and lifestyle modification on obese adults. Two hundred twenty four adults were assigned to receive the medication sibutramine alone, delivered by a primary care provider in eight visits of ten-minutes to 15 minutes each....

  • In this issue.  // Clinical Autonomic Research;Jun2005, Vol. 15 Issue 3, p181 

    Presents an overview of the articles published in the Volume 15 of the journal "Clinical Autonomic Research." Importance of baroreflex mediated vascular responses in the control of blood pressure during orthostasis; Effects of sibutramine on cardiovascular regulation; Causes of postural...

  • Sibutramine-induced mania as the first manifestation of bipolar disorder. Waszkiewicz, Napoleon; Zalewska-Szajda, Beata; Szajda, Sławomir Dariusz; Simonienko, Katarzyna; Zalewska, Anna; Szulc, Agata; Ładny, Jerzy Robert; Zwierz, Krzysztof // BMC Psychiatry;2012, Vol. 12 Issue 1, p43 

    Background: Sibutramine, used in obesity treatment, has been associated with many neuropsychiatric side effects including hypomanic and manic episodes. Hypomanic/manic episodes related to sibutramine treatment were earlier reported in patients who had previous history of bipolar disorder, after...

  • Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans. Talbot, Peter S.; Bradley, Stefan; Clarke, Cyril P.; Babalola, Kola O.; Philipp, Andrew W.; Brown, Gavin; McMahon, Adam W.; Matthews, Julian C. // Neuropsychopharmacology;Feb2010, Vol. 35 Issue 3, p741 

    Sibutramine is a centrally acting monoamine reuptake inhibitor prescribed as an appetite suppressant in the management of obesity. Its effects are mostly attributable to serotonin and norepinephrine transporter (SERT and NET, respectively) inhibition by its potent metabolites...

  • The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus -- an analysis from the SCOUT lead-in period. Weeke, Peter; Andersson, Charlotte; Fosbøl, Emil L.; Brendorp, Bente; Køber, Lars; Sharma, Arya M.; Finer, Nick; James, Philip T.; Caterson, Ian D.; Rode, Richard A.; Torp-Pedersen, Christian // BMC Endocrine Disorders;2010, Vol. 10, p3 

    Background: Obesity, type 2 diabetes mellitus (T2D) and unhealthy blood lipid profile are strongly associated with the risk of developing cardiovascular disease (CVD). We examined whether blood lipid changes with short term administration of the weight lowering drug, sibutramine and lifestyle...

  • Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review. Neovius, M.; Narbro, K. // International Journal of Obesity;Dec2008, Vol. 32 Issue 12, p1752 

    Aim:To review economic evaluations of weight loss drugs and compare reported incremental cost-effectiveness ratios (ICERs).Methods:A literature search was conducted for cost-effectiveness (CEAs) and cost-utility analyses (CUAs) of sibutramine, orlistat and rimonabant.Results:Fourteen unique...

  • Early first-trimester sibutramine exposure : pregnancy outcome and neonatal follow-up. De Santis, Marco; Straface, Gianluca; Cavaliere, Anna F.; Carducci, Brigida; Caruso, Alessandro // Drug Safety;2006, Vol. 29 Issue 3, p255 

    Background: Sibutramine is a drug that is used in the treatment of obesity. There are currently no epidemiological studies relating to sibutramine exposure in pregnancy. The objective of our study was to determine whether sibutramine exposure during pregnancy constitutes a risk...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics